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The cytosine deaminase APOBEC3G, in the absence of the human immunodeficiency virus type 1 (HIV-1)
accessory gene HIV-1 viral infectivity factor (vif), inhibits viral replication by introducing G3A hypermutation
in the newly synthesized HIV-1 DNA negative strand. We tested the hypothesis that genetic variants of
APOBEC3G may modify HIV-1 transmission and disease progression. Single nucleotide polymorphisms were
identified in the promoter region (three), introns (two), and exons (two). Genotypes were determined for 3,073
study participants enrolled in six HIV-AIDS prospective cohorts. One codon-changing variant, H186R in exon
4, was polymorphic in African Americans (AA) (f  37%) and rare in European Americans (f < 3%) or
Europeans (f  5%). For AA, the variant allele 186R was strongly associated with decline in CD4 T cells (CD4
slope on square root scale:1.86, P 0.009), The 186R allele was also associated with accelerated progression
to AIDS-defining conditions in AA. The in vitro antiviral activity of the 186R enzyme was not inferior to that
of the common H186 variant. These studies suggest that there may be a modifying role of variants of
APOBEC3G on HIV-1 disease progression that warrants further investigation.
In the adaptive struggle between host and pathogen, mam-
malian species have evolved an arsenal of strategies for ac-
quired and innate immunity to viral pathogens, which in turn
have evolved mechanisms to evade this surveillance. It has long
been observed that most T-cell lines support high replication
rates of both wild-type (wt) human immunodeficiency virus
type 1 (HIV-1) and HIV-1 with deletion of the accessory gene
encoding the viral infectivity factor (vif) but that primary T
cells, macrophages, and certain nonpermissive T-cell lines do
not support replication of vif HIV-1 (9, 30). Sheehy et al.
identified a cellular factor, CEM15, later shown to be the
cytidine deaminase APOBEC3G (27), a member of a family of
RNA editing enzymes that mediates HIV-1 vif suppression.
APOBEC3G has been shown to deaminate cytidine residues in
the newly synthesized DNA negative strand, causing G3A
hypermutation on the RNA genome of HIV-1 (13, 17, 21, 33).
APOBEC3G deamination of the minus strand of cDNA also
makes the newly synthesized DNA vulnerable to degradation
by uracil N-glycosylation (23). It has been demonstrated that
Vif potently reduces the amount of APOBEC3G encapsulated
in HIV-1 virions by associating with the cellular enzyme and
triggering its proteasomal degradation (23, 28, 29). HIV-1 Vif
does not prevent encapsidation of APOBEC3G proteins from
mouse, African green monkey, or rhesus monkey cells, sug-
gesting that species specificity of the Vif-APOBEC3G interac-
tion plays a role in restricting HIV-1 infection to humans (22).
Furthermore, APOBEC3G was found to act on other retrovi-
ruses in addition to HIV-1, suggesting that targeted DNA
deamination is a general innate defense mechanism against
retroviruses (13, 21, 22).
Since APOBEC3G is an important host factor that may
confer an intrinsic block to HIV-1 and possibly other human
pathogens that have an obligatory reverse transcription step,
we screened the APOBEC3G gene for both regulatory and
coding region variants that could modify APOBEC3G tran-
scription or amino acid sequence. We analyzed the effects of
six single nucleotide polymorphisms (SNPs) and their haplo-
types in five United States-based natural history cohorts and
the Swiss HIV cohort study for their influence on progression.
MATERIALS AND METHODS
Study participants. The United States-based cohort study groups consisted of
965 HIV-1 seroconverters, 763 seroprevalents, and 702 seronegatives, for a total
* Corresponding author. Mailing address: Basic Research Program,
SAIC Frederick, National Cancer Institute-Frederick Cancer Re-
search and Development Center, Frederick, MD 21702. Phone: (301)
846-5747. Fax: (301) 846-1909. E-mail: winkler@mail.ncifcrf.gov.
† Supplemental material for this article may be found at http://jvi
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of 2,430 participants (1,481 European Americans [EA] and 949 African Amer-
icans [AA]) enrolled in five natural history HIV-AIDS cohorts: AIDS Link to the
Intravenous Experience (ALIVE) (31), Multicenter AIDS Cohort Study
(MACS) (26), the San Francisco City Clinic Study (SFCC) (4), Hemophilia
Growth and Development Study (HGDS) (14), and the Multicenter Hemophilia
Cohort Study (MHCS) (11). The date of seroconversion after study enrollment
was estimated as the midpoint between the last seronegative and first seroposi-
tive HIV-1 antibody test; only individuals with less than 2 years’ elapsed time
between the two tests were included in the seroconverter progression analysis.
The censoring date was the earlier of the date of the last recorded visit or 31
December 1995 for the MACS, MHCS, HGDS, or SFCC cohorts or 31 July 1997
for the ALIVE cohort to avoid potential confounding by highly effective anti-
retroviral therapy (HAART); because administration of HAART was delayed in
the ALIVE cohort (5, 31), the later censoring date was used. The MACS, MHCS,
SFCC, and ALIVE cohorts consisted of both seroconverter (infected after study
enrollment) and seroprevalent (infected before study enrollment) individuals:
because of the potential for frailty bias among seroprevalents, only seroconvert-
ers enrolled in the MACS, MHCS, and SFCC cohorts were used in the survival
analysis. Longitudinal CD4 T-cell counts used for the random effects model were
available for each semiannual visit for 225 AA seroconverters (from enrollment
in 1988-1989 to 2003 or the censoring date) in the ALIVE cohorts and 643
seroprevalents (median follow-up time, 3.1 years) enrolled in the Swiss HIV
cohort (www.shcs.ch). High-risk exposed uninfected (HREU) individuals were
those with documented high-risk behaviors or documented exposure to contam-
inated blood products as previously described (2). DNA samples from 129
healthy blood donor Han Chinese were included in the study for allele frequen-
cies. The Institutional Review Board of participating institutes approved study
protocols and consent procedures.
Identification of DNA polymorphisms. Nucleotide polymorphisms in
APOBEC3G were discovered using a DNA panel consisting of 92 EA and 92 AA.
A nonisotopic RNA cleavage assay (NIRCA) was performed to detect polymor-
phisms (12). Overlapping PCR primers were designed to cover the putative 5
regulatory region, eight exons, exon-intron junctions, intron 1, and the 3 un-
translated region of the APOBEC3G gene according to GenBank sequences
AL022318 and AL078641. Gene-specific primers for APOBEC3G were designed
to avoid amplification of pseudogenes, other phorbolin-like genes, or APOBEC
genes (15). PCR primers and conditions are available upon request. PCR prod-
ucts that revealed aberrant bands by NIRCA analysis were purified and se-
quenced.
Genotyping of genetic variants. Genotypes were determined by PCR-restric-
tion fragment length polymorphism or TaqMan assays. PCR primer sequences,
TaqMan probes and primers, PCR conditions, and restriction enzymes used in
genotyping assays for each SNP are listed in Table S1 in the supplemental
material. PCR was carried out with 35 cycles of denaturing at 94°C for 30 s,
annealing at 54 to 60°C for 30 s, and extension at 72°C for 45 s. TaqMan assays
were performed according to the manufacturer’s manual (Perkin-Elmer). Prim-
ers are available on Table S1 in the supplemental material.
In vitro analysis. CD4 T cells from 128 healthy Caucasian blood donors were
isolated by anti-CD4 magnetic beads (Miltenyi Biotech, Bergisch Glabach, Ger-
many), cultured, and infected (106 cells) with 1,000 pg of p24 antigen of R5 clone
HIV NL4-3BaLenv. In addition, peripheral blood lymphocytes from 22 AA
donors were similarly infected. Samples from four donors were also infected with
the Vif-defective HIV-1 strain R9vif (32). After 7 days, p24 antigen production
was monitored by enzyme-linked immunosorbent assay (Abbott Laboratories).
Viral RNA was extracted from cells and supernatant and subjected to sequence
analysis to identify potential changes in the frequency of deamination.
Analysis of antiviral activity of APOBEC3G variants. The Vif-defective HIV-1
proviral clone R9vif was previously described (32). The plasmid expressing a
hemagglutinin-tagged form of APOBEC3G (27) was a kind gift from M. Malim
(University College, London, United Kingdom). The APOBEC3G 186R mutant
was constructed with the QuickChange Mutagenesis kit (Stratagene) and se-
quenced. HIV-1 was produced by transient transfection of 293T cells with Fu-
gene (Roche) in six-well plates. For this, 0.7 g of R9vif was used with either
an empty vector or different doses of the APOBEC3G-expressing vector. Thirty-
six hours after transfection, supernatant was collected and filtered. Virus titer
was scored by infecting HeLa-CD4-LacZ reporter cells. Virion infectivity was
normalized for particle amount, as measured by reverse transcriptase (RT)
activity assay.
Statistical analysis. The genetic effects of SNPs on HIV-1 infection suscepti-
bility were assessed by comparing genotypic frequencies between HIV-1 HREU
individuals and HIV-1 seroconverters with use of Fisher’s exact test. Kaplan-
Meier survival statistics and the Cox proportional hazards model were used to
assess the effects of SNPs and haplotypes on the rate of progression to AIDS.
Four end points were evaluated: time to less than 200 CD4 cells/mm3 (CD4 
200); AIDS-1987 and the expanded AIDS-1993 Centers for Disease Control and
Prevention case definitions (6, 7), and AIDS-related death. The significance of
genotypic associations and relative hazards (RH) for dominant and recessive
genetic models were determined with unadjusted and adjusted Cox model anal-
ysis. All P values are two-tailed. Genetic factors previously shown to affect
progression to AIDS in EA and AA groups were included as confounding
covariates in the adjusted Cox model analysis: CCR5 32, CCR2-64I, CCR5-P1,
HLA-B*27, HLA-B*57, HLA-B*35Px, and HLA class I homozygosity for EA (8,
10, 16, 24); CCR5-P1, RANTES-In1.1C, HLA-B*57, and HLA class I homozy-
gosity for AA (1, 8, 16, 24). CCR2-64I, HLA-B*27, and HLA-B*35Px were not
considered as covariates in AA due to absent or weak effects in our AA partic-
ipants, and CCR5 32 was not considered due to its rarity in AA. Participants
were stratified by sex and by age at seroconversion: 0 to 20, 20 to 40, and over
40 years (25).
A random effects linear model of CD4 T-cell trajectories from HIV-1 sero-
converters in the ALIVE study and HIV-1 seroprevalents in the Swiss cohort
study was used to provide estimates of mean CD4 T-cell measurements over time
while accounting for the correlation of repeated measurements within each
individual. The CD4 slope of each patient was modeled using a repeat measures
random effects model in STATA (Stata v8.0; College Station, Tex.) for the
ALIVE cohort or the Mlwin software for the Swiss cohort. The square root CD4
gradient was modeled as a linear function of estimated time since midpoint
(ALIVE) or imputed (Swiss) seroconversion dates. Additional covariates in-
cluded sex, age, and time since seroconversion for the ALIVE cohort and sex,
age (dichotomized at 40 years), intravenous drug use, race, and CCR5 32 (3) for
the Swiss cohort. Differences in CD4 gradient were compared to the group with
the most common genetic variant by use of a Wald test of the null hypothesis that
the difference is zero and the likelihood ratio test for models with and without
genetic variables. The change in mean square root CD4 T cells over time was
compared for APOBEC3G 186R/R (recessive genetic model) and R/H plus R/R
(dominant model). Additionally, to account for the potential confounding effects
of HAART in the ALIVE cohort, we fit the random effects model (i) by cen-
soring at 31 July 1997, before HAART was available to this population, and (ii)
by restricting the analysis to follow-up after 31 July 1997 and stratifying the
model to individuals who reported use or no use of HAART (31). These analyses
were done only for the ALIVE cohort because no significant effects of the
H186R polymorphism were observed in the predominantly European Swiss
cohort. Only these two cohorts had the complete CD4 T-cell follow-up data
available to our group for this analysis.
We quantified linkage disequilibrium (LD) between all pairs of biallelic loci by
use of the absolute value of Lewontin’s D (18). Absolute values of D range
from 0 for independence to 1 for complete LD between the pairs. P values
represent the null hypothesis of independence. Haplotypes were inferred by the
expectation maximization algorithm (19).
RESULTS
Identification of APOBEC3G variants. The genomic struc-
ture of APOBEC3G was predicted from a comparison of hu-
man DNA clone CTA-150C2 (GenBank sequence AL022318)
and clone RP3-494G10 (AL078641) with its mRNA sequence
(NM_021822). The human APOBEC3G gene spans 9 kb on
22q13.1-13.2 and has eight exons and seven introns. NIRCA
and DNA resequencing were employed to detect SNPs (15).
Seven SNPs were identified (Fig. 1a): three in the putative 5
regulatory region, F119F in exon 3, H186R in exon 4, and two
within introns. The genotype of each SNP was determined for
2,430 study participants enrolled in the United States-based
HIV-AIDS prospective cohorts, 643 participants in the Swiss
HIV cohort, and 129 healthy blood donor Han Chinese. The
allele frequencies are listed in Fig. 1b. The single codon-chang-
ing variant, H186R, was rare in EA and European Caucasians
(f  0.03 and 0.05) but frequent in AA (f  0.37).
LD and haplotypes of APOBEC3G variants. Pairwise tests of
LD were performed among all APOBEC3G SNPs except for
the rare 	199G/A SNP. Strong LD was observed between all
APOBEC3G SNPs (1.0  D  0.923, P  1.1 
 10	3 in EA
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and 1.0  D  0.880, P  1.1 
 10	5 in AA, respectively)
(Fig. 1c). There were 13 and 14 haplotypes in AA and EA,
respectively. The six most frequent haplotypes were shared in
both races and accounted for more than 98% of AA or EA
chromosomes (Fig. 1b).
Effect of APOBEC3G SNPs and haplotypes on susceptibility
to HIV-1 infection. We compared APOBEC3G allele, geno-
type, and haplotype frequencies for HREU individuals or
HIV-1 seronegatives to HIV-1-infected seroconverters for
dominant and recessive genetic models. No associations were
observed for any SNP or haplotype (see Table S2 in the sup-
plemental material), suggesting that APOBEC3G variants have
no obvious effect on HIV-1 transmission.
Effect of APOBEC3G SNPs and haplotypes on AIDS pro-
gression. The influences of APOBEC3G SNP alleles and hap-
lotypes on AIDS progression were evaluated for dominant and
recessive genetic models among EA (n  673) and AA (n 
292) HIV-1 seroconverters by use of the Cox proportional
hazards model. Survival analyses with and without adjustments
for the influence of AIDS-restriction gene covariates are listed
in Table 1 and shown in Fig. 2. In the unadjusted analysis, the
186R/R genotype tended to be associated with disease progres-
sion to AIDS-1993, AIDS-1987, and death (RH 1.43 to 1.82,
P  0.059 to 0.16). After adjusting for the potentially con-
founding effects of other genetic factors, the 186R/R genotype
was associated with accelerated rate of progression to AIDS-
1993, AIDS-1987, and death (RH  1.94, 2.94, and 3.38, re-
spectively; P  0.024, 0.005, and 0.008, respectively). To un-
derstand why the 186R/R association was masked in the
unadjusted analysis, each of the genetic covariates was sequen-
tially used in the adjusted Cox model. The covariate RANTES-
FIG. 1. Gene map, LD, and haplotypes of APOBEC3G. (a) Exon
distribution (not to scale) and genomic locations of the SNPs. Coding
exons are marked by shaded blocks, and the 5 and 3 untranslated
regions are marked by white blocks. The SNPs were numbered accord-
ing to the first base of the translation start site for those located in the
putative promoter region, of reference sequence AL022318 for in-
tronic SNPs, and of the amino acid sequence (NP_068594). (b) The six
most frequent haplotypes and their frequencies in AA, EA, and Chi-
nese (CH). (c) Detailed LD parameter D for the six SNPs in AA
(below the diagonal) and EA (above the diagonal); **, P  0.001; ***,
P  0.0001.
TABLE 1. Cox model analysis of the effects of APOBEC3G SNPs on AIDS progressiona
SNP Race Model
CD4 200 AIDS-1993 AIDS-1987 Death
RH 95% CI P RH 95% CI P RH 95% CI P RH 95% CI P
Unadjustedb
197193Cc EA Dom 1.00 0.62–1.61 0.990 0.91 0.59–1.41 0.680 1.03 0.64–1.67 0.890 0.84 0.48–1.47 0.550
AA Dom 1.29 0.84–1.97 0.240 1.23 0.84–1.81 0.290 1.28 0.74–2.20 0.370 1.16 0.57–2.38 0.680
Rec 1.34 0.82–2.19 0.240 1.47 0.94–2.30 0.089 1.88 1.03–3.44 0.040 1.96 0.91–4.21 0.087
186R EA Dom 0.98 0.62–1.56 0.930 0.90 0.59–1.37 0.610 1.04 0.65–1.66 0.880 0.87 0.51–1.50 0.620
AA Dom 1.34 0.87–2.04 0.180 1.32 0.90–1.94 0.160 1.37 0.79–2.38 0.270 1.12 0.55–2.31 0.750
Rec 1.28 0.77–2.10 0.340 1.43 0.91–2.26 0.120 1.82 0.98–3.39 0.059 1.76 0.79–3.92 0.170
199376C EA Dom 0.99 0.76–1.28 0.930 1.02 0.80–1.30 0.870 1.10 0.83–1.47 0.520 1.12 0.82–1.53 0.460
Rec 1.04 0.82–1.32 0.730 1.28 1.04–1.58 0.021 1.36 1.07–1.73 0.013 1.37 1.06–1.77 0.016
AA Dom 1.16 0.76–1.77 0.500 1.19 0.81–1.75 0.390 1.01 0.58–1.77 0.970 0.90 0.42–1.92 0.780
Adjustedd
197193Cc EA Dom 0.95 0.58–1.56 0.830 0.95 0.61–1.49 0.820 1.10 0.67–1.82 0.700 0.87 0.48–1.56 0.630
AA Dom 1.15 0.70–1.90 0.570 1.09 0.71–1.69 0.690 1.37 0.75–2.50 0.310 1.50 0.65–3.45 0.340
Rec 1.59 0.83–3.03 0.160 2.03 1.16–3.57 0.013 3.06 1.49–6.29 0.002 3.76 1.60–3.84 0.002
186R EA Dom 0.91 0.56–1.48 0.720 0.91 0.59–1.41 0.670 1.07 0.66–1.74 0.770 0.88 0.50–1.55 0.670
AA Dom 1.14 0.70–1.88 0.600 1.14 0.74–1.78 0.550 1.47 0.79–2.73 0.220 1.45 0.63–3.37 0.380
Rec 1.46 0.75–2.84 0.270 1.94 1.09–3.44 0.024 2.94 1.39–6.21 0.005 3.38 1.38–8.27 0.008
199376C EA Dom 1.08 0.82–1.42 0.580 1.11 0.87–1.43 0.390 1.21 0.90–1.63 0.200 1.16 0.84–1.59 0.370
Rec 1.11 0.87–1.42 0.400 1.28 1.03–1.60 0.024 1.34 1.05–1.73 0.020 1.38 1.05–1.80 0.020
AA Dom 1.06 0.64–1.76 0.810 1.02 0.65–1.60 0.940 0.87 0.46–1.64 0.670 0.74 0.31–1.80 0.510
a Analysis was done in seroconverters (n 656 and 292 in EA and AA, respectively) for dominant (Dom) or recessive (Rec) model; Recessive model was not assessed
in groups with five or fewer individuals carrying the genotype; results for the other three SNPs are listed in Tables 3 in the supplemental material.
b Results were unadjusted for covariates.
c Missing 197193T/C genotype for one patient compared to H186R.
d Results were adjusted with covariates CCR5 32 and four HLA alleles (Zyg_N, B27, B35Px, and B57) for EA and covariates Zyg_N. B57, CCR5-P1, and
RANTES-In1.1C for AA.
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In1.1C alone revealed nearly the full strength of the associa-
tion (data not shown); however, no interaction was observed
between APOBEC3G 186R and RANTES-In1.1C (P  0.35),
consistent with the current understanding of the functional
pathways of the two genes.
A weak but statistically significant protective tendency was
observed for the intron 4 APOBEC3G-199376C allele for
AIDS-1993, AIDS-1987, and death in the recessive model for
EA, both without and with adjustment (RH  1.36 to 1.58, P
 0.01 to 0.003) for potential confounding genetic factors
(Table 1). Results for SNPs with no significant associations are
listed in Table S3 in the supplemental material. APOBEC3G-
197193C, located in intron 2, is in complete and nearly abso-
lute LD with 186R, thus showing very similar associations
(Table S3 in the supplemental material).
Since the alleles within the APOBEC3G gene are in com-
plete or near-complete LD, we considered the combination of
alleles that are inherited together on a single chromosomal
segment (haplotype) since these more closely represent the
natural condition. Since the 186R allele is found only on hap-
lotype 1 (Hap 1), the associations observed for Hap 1 were
quite similar to that of the 186R allele (Tables 1 and 2; Fig. 2).
The slight differences observed in RH and P values are due to
individuals missing one or more genotypes. Modest accelerat-
ing effects to AIDS-1987 and death were observed for Hap 4 in
EA. Conversely, Hap 3, which contains neither 186R nor
199376C, was slightly protective in both AA and EA for the
early outcomes, CD4  200 or AIDS-1993 (P  0.01 to 0.10)
(Table 2).
Effect of H186R on overall CD4 T-cell slope gradients. We
evaluated the effect of APOBEC3G-H186R on CD4 slope us-
ing the random effects model for the ALIVE and Swiss cohorts
(Table 3). Among 225 AA seroconverters enrolled in the
ALIVE study, individuals carrying at least one copy of
APOBEC3G-186R had a 	1.86 (95% confidence interval [CI],
	3.25, 	0.45; P  0.009) lower mean CD4 T-cell trajectory
than did the reference 186H/H group. Analysis restricted to
217 individuals who were censored at 31 July 1997 had a
similar decrease in mean CD4 T-cell trajectory (	1.51; 95%
CI, 	2.96, 	0.65; P  0.041) which persisted after increased
availability of HAART (	2.25 lower; 95% CI,	4.13,	0.37; P
 0.019). For the dominant genetic model in the Swiss sero-
prevalent cohort, 186R (H/R, n  57; R/R, n  5) was found
to be marginally associated with protection with a gradient
difference of 0.29 (95% CI, 	0.04, 0.62; P  0.08) relative to
the reference 186H/H genotype (n  581). The low number of
homozygotes precluded an analysis of the recessive model.
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FIG. 2. Kaplan-Meier survival curves of HIV-1 progression to
AIDS-1987 after seroconversion for the three genotypes of
APOBEC3G-H186R in AA. RH and Wald P values are from an ad-
justed Cox model analysis, and log rank P value is for the Kaplan-
Meier statistic.
TABLE 2. Cox model analysis of APOBFC3G haplotypes on AIDS progression, adjusting for covariatesa
Group and
haplotype Model
CD4  200 AIDS-1993 AIDS-1987 Death
RH 95% CI P RH 95% CI P RH 95% CI P RH 95% CI P
AA (n  268)b
Hap 1 Rec 1.80 0.92–3.53 0.088 2.01 1.10–3.66 0.022 2.94 1.33–6.49 0.008 3.60 1.46–8.87 0.005
Dom 1.41 0.83–2.40 0.200 1.25 0.78–1.99 0.351 1.72 0.88–3.36 0.111 1.89 0.79–4.52 0.153
Hap 2 Dom 1.00 0.62–1.61 0.990 1.01 0.66–1.57 0.953 0.54 0.29–1.02 0.057 0.39 0.16–0.96 0.040
Hap 3 Dom 0.46 0.25–0.85 0.013 0.52 0.31–0.88 0.015 0.90 0.47–1.72 0.747 0.89 0.39–2.06 0.791
Hap 4 Dom 1.19 0.66–2.17 0.564 0.96 0.56–1.67 0.900 0.88 0.40–1.93 0.759 0.93 0.31–2.77 0.890
Hap 5 Dom 0.64 0.30–1.37 0.252 0.95 0.51–1.77 0.878 2.11 0.95–4.66 0.065 1.14 0.37–3.54 0.816
Hap 6 Dom 1.49 0.83–2.66 0.183 1.65 0.97–2.80 0.063 1.04 0.45–2.40 0.930 0.98 0.31–3.10 0.970
EA (n  605)c
Hap 1 Dom 0.94 0.57–1.56 0.818 0.94 0.60–1.48 0.795 1.04 0.63–1.73 0.866 0.83 0.46–1.49 0.534
Hap 2 Dom 1.00 0.79–1.27 1.000 0.94 0.76–1.16 0.566 0.87 0.68–1.12 0.274 0.86 0.66–1.13 0.277
Hap 3 Dom 0.73 0.50–1.06 0.099 0.76 0.54–1.06 0.102 0.85 0.58–1.25 0.421 0.73 0.47–1.13 0.153
Hap 4 Dom 1.25 0.96–1.63 0.103 1.36 1.07–1.73 0.011 1.35 1.02–1.78 0.034 1.58 1.18–2.13 0.003
Hap 5 Dom 1.11 0.79–1.57 0.536 0.95 0.69–1.30 0.752 0.99 0.68–1.43 0.959 1.04 0.69–1.55 0.864
Hap 6 Dom 1.05 0.83–1.34 0.707 1.08 0.86–1.35 0.503 1.15 0.88–1.49 0.304 1.06 0.80–1.40 0.694
a The rate of progression to four AIDS end points in patients carrying one or two copies of the haplotype was compared with that in patients without that haplotype.
CI, RH, and significance were calculated with the use of the Cox model. Both Dom (dominant) and Rec (recessive) genetic models were tested, but results for the
recessive model were not shown if they were not significant. The analyses were adjusted unless indicated as unadjusted.
b Adjusted for HLA Zyg_N, B57, CCR5-P1, and RANTES-In1.1.
c Adjusted for CCR5-P1, CCR5 32, and four HLA alleles (Zyg_N, B27, B35Px, and B57).
VOL. 78, 2004 INFLUENCE OF APOBEC3G GENETIC VARIANTS ON AIDS PROGRESSION 11073
 o
n
 January 13, 2016 by NO
VA SO
UTHEASTERN UNIV
http://jvi.asm.org/
D
ow
nloaded from
 
Estimates were not modified significantly after adjusting for
the potentially confounding effects of other genetic factors.
In vitro antiviral activity of 186R enzyme. We tested whether
mutating histidine to arginine at position 186 could influence the
inhibitory potential of APOBEC3G. A single-round assay was
used to measure the infectivity of wt and vif particles produced
by transient transfection of 293T cells, in the presence of different
doses of the wt or mutated cellular factor (Fig. 3). We found that
the 186R mutant was fully able to inhibit viral infectivity.
The in vitro assessment of the role of H186R variants in
influencing viral infectivity or deamination was completed by us-
ing peripheral mononuclear cells collected from healthy blood
donors representing the various genotypes. Cells were infected
with the R5-tropic clone HIV NL4-3BaLenv and by the Vif-
deficient R9vif. There were no measurable differences in cell
permissiveness to HIV infection in the in vitro system for the
various H186R genotypes: mean and standard deviation of log
p24 picograms per milliliter after 7 days of culture were 4.96 
4.79 for cells from 112 Caucasian donors representing the com-
mon H186 genotype versus 4.98  4.78 for cells from 13 Cauca-
sian donors carrying the 186R variant, P  0.7. Similarly, there
were no measurable differences in cell permissiveness to HIV
infection in cells from AA donors: mean and standard deviation
of log p24 picograms per milliliter after 7 days of culture were 4.64
 0.83 for cells from 11 AA donors representing the common
H186 genotype versus 4.93  0.27 for cells from 11 AA donors
homozygous for the 186R variant, P 0.49. This higher viral level
with 186R, though not significant, warrants further elucidation in
a large number of samples. The Vif-deficient R9vif strain was
confirmed noninfectious for the various donor cells. No specific
pattern of deamination of cytidine residues reflecting changes
associated with the enzyme alleles was observed in the viral prog-
eny emerging after 7 days of replication in the various cell pop-
ulations (data not shown).
DISCUSSION
We have investigated the role of APOBEC3G SNPs and
haplotypes on HIV-1 infection and progression in six longitu-
dinal HIV-1 cohorts. With use of survival analysis, the 186R/R
FIG. 3. Antiviral activity of APOBEC3G 186H and 186R variants.
(A) 293T cells were transfected with R9 HIV-1 or with the Vif-defective
R9vif proviral clone in the presence of empty vector, wt hAPOBEC3G
(H186R), or 186R APOBEC3G-expressing vector. Supernatant was fil-
tered, and viral titer was scored by infecting HeLa-CD4-LacZ reporter
cells not expressing APOBEC3G. Virion infectivity is normalized for
particle amount, as measured by RT activity assay. (B) In a second ex-
periment, 293T cells were transfected with R9vif in the presence of four
different doses of either an empty vector, wt hAPOBEC3G, or 186R
APOBEC3G-expressing vector. The four ratios of APOBEC3G to R9vif
are 0.5 (dark grey), 1 (light grey), 2 (white), and 3 (stippled). Analyses
were done in duplicate, with bars representing the standard deviations.
TABLE 3. Effects of APOBEC3G H186R on overall CD4 T-cell slope gradients in the ALIVE seroconverter and Swiss seroprevalent
cohortsa
Genetic model and cohort
Total no. of:
CD4 T-cell slope P (95% CI)
Individuals Observations
APOBEC3G 186 H/R and R/R
ALIVE seroconverters (all)b 225 2,852 	1.86 0.009 (	3.26, 	0.45)
ALIVE SC censored 7/97c 217 1,741 	1.51 0.041 (	2.96, 	0.65)
ALIVE SC 7/97–1/03d 151 1,120 	2.25 0.019 (	4.13, 	0.37)
Swiss seroprevalents 643 4,501 0.29 0.080 (	0.04, 0.62)
APOBEC3G 186 R/R only
ALIVE seroconverters (all)b 225 2,852 	1.62 0.09 (	3.48, 0.24)
ALIVE SC censored 7/97c 217 1,741 	2.21 0.11 (	4.93, 0.49)
ALIVE SC 7/97–1/03d 151 1,120 	2.02 0.14 (	4.72, 0.68)
a For the ALIVE seroconverters (SC) all analyses were adjusted for age and sex. For the Swiss seroprevalent cohort, analyses were adjusted for age, sex, race, CCR5
32, and intravenous drug use. Only five homozygotes were observed in the Swiss cohort; therefore, a recessive genetic model was not tested.
b Observation period for all seroconverters not censored for HAART.
c Observation period before onset of HAART (July 1997).
d Observation period after onset of HAART therapy (July 1997 to January 2003).
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genotype was shown to be significantly associated with rapid
progression to AIDS and death in AA. With use of the random
effects model, 186R carriers had a more rapid decline of CD4
T-cell slope than did individuals homozygous for H186.
The discrepancies between results from the two analyses
may reflect the fact that the random effects model has in-
creased resolution with many more observation outcomes. Al-
though the effects of 186R do not reach significance in the Cox
model analysis with use of a CD4 cell count of 200 as an
outcome in AA, the tendency towards more rapid CD4 loss in
186R carriers is consistent with the CD4 trajectory in this
group. In contrast, the effects of 186R on CD4 slope in the
Swiss Caucasian seroprevalent cohort tended to be slightly
protective, possibly because of the modifying influence of as-
yet-undetected polymorphisms, differences in cohort design, or
the low allele frequency of 186R in this group. The intronic
199376C allele carried on Hap 4 and Hap 6 was associated with
a modest accelerating effect to AIDS and death. Hap 4 was
associated with rapid progression in only EA, and Hap 6
showed a similar tendency only in AA. These results suggest
that 199376G/C is not itself causal but may be tracking by LD
an allele as yet undetected.
It has been demonstrated that a moderate amount of human
APOBEC3G causes a threefold decrease in infectivity of the
wt HIV-1, suggesting that alterations that affect APOBEC3G
activity or expression level may influence HIV-1 replication
(22). H186R is located in the leucine-rich region possibly in-
volved in protein-protein interaction, either with complemen-
tation factors and/or in homodimer formation (15). Disruption
of this region could modify editing functions as a result of
altered assembly of the enzyme (20). However, there is no
functional evidence for a defect in the antiviral activity of
APOBEC3G-186R in our preliminary in vitro experiments. It
would be interesting to determine if 186R increases G-to-A
mutation and breadth of the quasispecies variation, as this
would promote the emergence of immune escape mutants.
APOBEC3G haplotypes are distributed differently among
individuals of Asian, European, and African ancestry. This
observation indicates that APOBEC3G haplotypes were possi-
bly shaped through different evolutionary or historical events
in geographic populations. The different genetic backgrounds
in allele frequencies, LD, and haplotype architecture observed
among world populations may account for, at least in part,
population-specific genetic effects on HIV-1 disease.
ACKNOWLEDGMENTS
We gratefully acknowledge the participants, their families, and their
clinicians who participated in the ALIVE, MACS, HGDS, MHCS,
SFCC, and SHCS studies. We thank Beth Binns-Roemer, Yuchun
Zhou, Zhengmei Liu, and Kui Gong for excellent technical assistance
and Daniele Fallin for helpful comments.
This study was funded in whole or in part with federal funds from
the National Cancer Institute, National Institutes of Health, under
contract no. NO1-CO-124000; the National Institute on Drug Abuse,
National Institutes of Health, under grant DA04334; and the Swiss
National Science Foundation and Leenaards Foundation.
The content of this publication does not necessarily reflect the views
or policies of the Department of Health and Human Services, nor does
mention of trade names, commercial products, or organizations imply
endorsement by the U.S. Government.
REFERENCES
1. An, P., G. W. Nelson, L. Wang, S. Donfield, J. J. Goedert, J. Phair, D. Vlahov,
S. Buchbinder, W. L. Farrar, W. Modi, S. J. O’Brien, and C. A. Winkler.
2002. Modulating influence on HIV/AIDS by interacting RANTES gene
variants. Proc. Natl. Acad. Sci. USA 99:10002–10007.
2. An, P., D. Vlahov, J. B. Margolick, J. Phair, T. R. O’Brien, J. Lautenberger,
S. J. O’Brien, and C. A. Winkler. 2003. A tumor necrosis factor-alpha-
inducible promoter variant of interferon-gamma accelerates CD4 T cell
depletion in human immunodeficiency virus-1-infected individuals. J. Infect.
Dis. 188:228–231.
3. Bleiber, G., M. May, C. Suarez, R. Martinez, C. Marzolini, M. Egger, and A.
Telenti. 2004. MDR1 genetic polymorphism does not modify either cell
permissiveness to HIV-1 or disease progression before treatment. J. Infect.
Dis. 189:583–586.
4. Buchbinder, S. P., M. H. Katz, N. A. Hessol, P. M. O’Malley, and S. D.
Holmberg. 1994. Long-term HIV-1 infection without immunologic progres-
sion. AIDS 8:1123–1128.
5. Celentano, D. D., N. Galai, A. K. Sethi, N. G. Shah, S. A. Strathdee, D.
Vlahov, and J. E. Gallant. 2001. Time to initiating highly active antiretroviral
therapy among HIV-infected injection drug users. AIDS 15:1707–1715.
6. Centers for Disease Control. 1987. Revision of the CDC surveillance case
definition for acquired immunodeficiency syndrome. Council of State and
Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases.
Morb. Mortal. Wkly. Rep. 36(Suppl. 1):1S–15S.
7. Centers for Disease Control and Prevention. 1992. 1993 revised classification
system for HIV infection and expanded surveillance case definition for AIDS
among adolescents and adults. Morb. Mortal. Wkly. Rep. 41:1–19.
8. Dean, M., M. Carrington, C. Winkler, G. A. Huttley, M. W. Smith, R.
Allikmets, J. J. Goedert, S. P. Buchbinder, E. Vittinghoff, E. Gomperts, S.
Donfield, D. Vlahov, R. Kaslow, A. Saah, C. Rinaldo, R. Detels, and S. J.
O’Brien. 1996. Genetic restriction of HIV-1 infection and progression to
AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth
and Development Study, Multicenter AIDS Cohort Study, Multicenter He-
mophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science
273:1856–1862.
9. Gabuzda, D. H., K. Lawrence, E. Langhoff, E. Terwilliger, T. Dorfman, W. A.
Haseltine, and J. Sodroski. 1992. Role of vif in replication of human immu-
nodeficiency virus type 1 in CD4 T lymphocytes. J. Virol. 66:6489–6495.
10. Gao, X., G. W. Nelson, P. Karacki, M. P. Martin, J. Phair, R. Kaslow, J. J.
Goedert, S. Buchbinder, K. Hoots, D. Vlahov, S. J. O’Brien, and M. Car-
rington. 2001. Effect of a single amino acid change in MHC class I molecules
on the rate of progression to AIDS. N. Engl. J. Med. 344:1668–1675.
11. Goedert, J. J., C. M. Kessler, L. M. Aledort, R. J. Biggar, W. A. Andes, G. C.
White II, J. E. Drummond, K. Vaidya, D. L. Mann, M. E. Eyster, et al. 1989.
A prospective study of human immunodeficiency virus type 1 infection and
the development of AIDS in subjects with hemophilia. N. Engl. J. Med.
321:1141–1148.
12. Goldrick, M. M., G. R. Kimball, Q. Liu, L. A. Martin, S. S. Sommer, and
J. Y. Tseng. 1996. NIRCA: a rapid robust method for screening for unknown
point mutations. BioTechniques 21:106–112.
13. Harris, R. S., K. N. Bishop, A. M. Sheehy, H. M. Craig, S. K. Petersen-
Mahrt, I. N. Watt, M. S. Neuberger, and M. H. Malim. 2003. DNA deami-
nation mediates innate immunity to retroviral infection. Cell 113:803–809.
14. Hilgartner, M. W., S. M. Donfield, A. Willoughby, C. F. Contant, Jr., B. L.
Evatt, E. D. Gomperts, W. K. Hoots, J. Jason, K. A. Loveland, S. M. McK-
inlay, et al. 1993. Hemophilia growth and development study. Design, meth-
ods, and entry data. Am. J. Pediatr. Hematol. Oncol. 15:208–218.
15. Jarmuz, A., A. Chester, J. Bayliss, J. Gisbourne, I. Dunham, J. Scott, and N.
Navaratnam. 2002. An anthropoid-specific locus of orphan C to U RNA-
editing enzymes on chromosome 22. Genomics 79:285–296.
16. Kaslow, R. A., M. Carrington, R. Apple, L. Park, A. Munoz, A. J. Saah, J. J.
Goedert, C. Winkler, S. J. O’Brien, C. Rinaldo, R. Detels, W. Blattner, J.
Phair, H. Erlich, and D. L. Mann. 1996. Influence of combinations of human
major histocompatibility complex genes on the course of HIV-1 infection.
Nat. Med. 2:405–411.
17. Lecossier, D., F. Bouchonnet, F. Clavel, and A. J. Hance. 2003. Hypermu-
tation of HIV-1 DNA in the absence of the Vif protein. Science 300:1112.
18. Lewontin, R. C. 1964. The interaction of selection and linkage. II. Optimum
models. Genetics 50:757–782.
19. Long, J. C., R. C. Williams, and M. Urbanek. 1995. An E-M algorithm and
testing strategy for multiple-locus haplotypes. Am. J. Hum. Genet. 56:799–
810.
20. MacGinnitie, A. J., S. Anant, and N. O. Davidson. 1995. Mutagenesis of
apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA
editing enzyme, reveals distinct domains that mediate cytosine nucleoside
deaminase, RNA binding, and RNA editing activity. J. Biol. Chem. 270:
14768–14775.
21. Mangeat, B., P. Turelli, G. Caron, M. Friedli, L. Perrin, and D. Trono. 2003.
Broad antiretroviral defence by human APOBEC3G through lethal editing
of nascent reverse transcripts. Nature 424:99–103.
22. Mariani, R., D. Chen, B. Schrofelbauer, F. Navarro, R. Konig, B. Bollman,
VOL. 78, 2004 INFLUENCE OF APOBEC3G GENETIC VARIANTS ON AIDS PROGRESSION 11075
 o
n
 January 13, 2016 by NO
VA SO
UTHEASTERN UNIV
http://jvi.asm.org/
D
ow
nloaded from
 
C. Munk, H. Nymark-McMahon, and N. R. Landau. 2003. Species-specific
exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21–31.
23. Marin, M., K. M. Rose, S. L. Kozak, and D. Kabat. 2003. HIV-1 Vif protein
binds the editing enzyme APOBEC3G and induces its degradation. Nat.
Med. 9:1398–1403.
24. Martin, M. P., M. Dean, M. W. Smith, C. Winkler, B. Gerrard, N. L.
Michael, B. Lee, R. W. Doms, J. Margolick, S. Buchbinder, J. J. Goedert,
T. R. O’Brien, M. W. Hilgartner, D. Vlahov, S. J. O’Brien, and M. Car-
rington. 1998. Genetic acceleration of AIDS progression by a promoter
variant of CCR5. Science 282:1907–1911.
25. O’Brien, S. J., G. W. Nelson, C. A. Winkler, and M. W. Smith. 2000. Poly-
genic and multifactorial disease gene association in man: lessons from AIDS.
Annu. Rev. Genet. 34:563–591.
26. Phair, J., L. Jacobson, R. Detels, C. Rinaldo, A. Saah, L. Schrager, and A.
Munoz. 1992. Acquired immune deficiency syndrome occurring within 5
years of infection with human immunodeficiency virus type-1: the Multi-
center AIDS Cohort Study. J. Acquir. Immune Defic. Syndr. 5:490–496.
27. Sheehy, A. M., N. C. Gaddis, J. D. Choi, and M. H. Malim. 2002. Isolation
of a human gene that inhibits HIV-1 infection and is suppressed by the viral
Vif protein. Nature 418:646–650.
28. Sheehy, A. M., N. C. Gaddis, and M. H. Malim. 2003. The antiretroviral
enzyme APOBEC3G is degraded by the proteasome in response to HIV-1
Vif. Nat. Med. 9:1404–1407.
29. Stopak, K., C. de Noronha, W. Yonemoto, and W. C. Greene. 2003. HIV-1
Vif blocks the antiviral activity of APOBEC3G by impairing both its trans-
lation and intracellular stability. Mol. Cell 12:591–601.
30. Strebel, K., D. Daugherty, K. Clouse, D. Cohen, T. Folks, and M. A. Martin.
1987. The HIV A’ (sor) gene product is essential for virus infectivity. Nature
328:728–730.
31. Vlahov, D., N. Graham, D. Hoover, C. Flynn, J. G. Bartlett, J. B. Margolick,
C. M. Lyles, K. E. Nelson, D. Smith, S. Holmberg, and H. Farzadegan. 1998.
Prognostic indicators for AIDS and infectious disease death in HIV-infected
injection drug users: plasma viral load and CD4 cell count. JAMA 279:35–
40.
32. von Schwedler, U., J. Song, C. Aiken, and D. Trono. 1993. Vif is crucial for
human immunodeficiency virus type 1 proviral DNA synthesis in infected
cells. J. Virol. 67:4945–4955.
33. Zhang, H., B. Yang, R. J. Pomerantz, C. Zhang, S. C. Arunachalam, and L.
Gao. 2003. The cytidine deaminase CEM15 induces hypermutation in newly
synthesized HIV-1 DNA. Nature 424:94–98.
11076 AN ET AL. J. VIROL.
 o
n
 January 13, 2016 by NO
VA SO
UTHEASTERN UNIV
http://jvi.asm.org/
D
ow
nloaded from
 
